Last updated on February 2020

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

Brief description of study

The purpose of this study is to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in COPD patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple combination therapy of LABA, LAMA and ICS with respect to trough FEV1 change from baseline after 12 weeks of treatment.

Clinical Study Identifier: NCT04072887

Find a site near you

Start Over

Novartis Investigative Site

Yamagata city, Japan
  Connect »